Scholar Rock Beats by $0.04 on $0.57 Million Revenue, Stock Falls 4.8%

Scholar Rock (NASDAQ:SRRK) reported a quarterly loss of $0.81 per share on Tuesday, beating the analyst consensus of a $0.85 loss by $0.04. Revenue came in at $0.57 million against expectations of $0.30 million. A year earlier, the company lost $0.90 per share. The market's verdict was unkind all the same: the shares fell 4.8%, or $2.23, to $44.38 by midday Thursday on volume of 100,091 shares — barely a tenth of the 1,458,204-share daily average.

The gap between the beat and the selloff deserves scrutiny. The numbers that moved the stock sit inside the company's conference call, and several of them cut both ways.

What did the ISEMBYLD launch actually deliver?

The U.S. launch of ISEMBYLD showed broad early demand. Enrollments came from across the country, included treatment-naive patients as well as children and adults, and reached more than one-third of the top 140 SMA treatment centers within six weeks. That is a genuine commercial signal.

Yet the company conceded that prescription-to-infusion timelines can exceed 60 to 90 days as patients work through prior authorization, payer policies and hospital formularies. Access delays are likely to push many initial infusions into 2027. An ISEMBYLD-specific J-code is expected on April 1, 2027 — a date that places the revenue inflection nearly eighteen months out. Takeaway: demand is early evidence, not booked revenue.

Where does the regulatory pipeline stand?

Apitegromab's European application was resubmitted and validated, with a CHMP opinion expected in the first half of 2027. Japan accepted the application for priority review, supporting a potential launch near the end of 2027. On the research side, dosing began in the phase II FORGE study in FSHD, enrollment continues in the under-two OPAL study, and SRK-439 phase I dosing is progressing, with top-line data expected by year-end and an update planned for early 2027. Each milestone carries a date; none delivers certainty before 2027.

Is the balance sheet secure enough to wait?

The company strengthened its position with a $205 million agreement to sell its priority review voucher. It reported $413.6 million in cash, equivalents and marketable securities at quarter-end and said it does not need an equity offering at this time. "At this time" is the operative phrase — dilution is deferred, not ruled out, and the runway must carry the company to those 2027 catalysts.

How did analysts respond?

The desk reaction split sharply.

• HC Wainwright improved its Q4 2026 and FY2026 EPS estimates to losses of $0.75 and $3.23 per share respectively, kept a Buy rating and raised its target from $65.00 to $70.00.
• The same firm cut FY2027–FY2030 projections, including FY2029 from a $0.47 profit to a $0.12 loss and FY2030 from $1.44 to $1.00.
• Wolfe Research downgraded the stock from "Outperform" to "Peer Perform" on Thursday.
• Evercore reaffirmed "outperform" with a $72.00 target on September 15; Jefferies lifted its objective from $57.00 to $65.00 on September 14; Citigroup went from $60.00 to $74.00 the same day.

In aggregate, three analysts rate the stock Strong Buy, ten Buy, two Hold and two Sell — an average rating of Moderate Buy and an average target of $67.67, roughly 52% above the current price. Consensus targets, however, did not prevent Thursday's decline.

What are the valuation and insider signals?

Scholar Rock carries a market capitalization of $5.40 billion, a price-to-earnings ratio of -13.18 and a beta of 0.78. The current ratio and quick ratio both stand at 7.02, with debt-to-equity at 0.77. The stock has traded between a one-year low of $29.35 and a high of $61.76; the 50-day moving average is $46.64 and the 200-day average is $48.23 — the shares now sit below both.

Director Srinivas Akkaraju bought 146,970 shares on October 26 at an average of $41.59, a total of $6,112,482.30, lifting his holding to 6,380,517 shares worth roughly $265.4 million and increasing his ownership by 2.36%. Insiders own 10.30% of the company. An insider buying near the lows is a signal; it is not a guarantee.

Scholar Rock, based in Cambridge, Massachusetts, develops medicines targeting growth factors and signaling proteins, with its lead program apitegromab, a selective myostatin inhibitor for spinal muscular atrophy, studied alongside existing SMA therapies to improve motor function.

The beat was real, the cash is real, and the catalysts are dated — but almost every one of them lands in 2027.